EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 · Journal of Hepatology · 11K citations
https://doi.org/10.1016/j.jhep.2018.03.019
F
Fabio Piscaglia
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
817
Papers
49.3K
Citations
88
h-index
324
i10-index
Fabio Piscaglia is an academic researcher from Azienda USL di Bologna. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation. The author has an h-index of 88, co-authored 695 publications.
ORCID: 0000-0001-8264-1845Papers by this author
worksLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
2018 · The Lancet · 5,257 citations
https://doi.org/10.1016/s0140-6736(18)30207-1
EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)
2017 · Ultraschall in der Medizin - European Journal of Ultrasound · 988 citations
https://doi.org/10.1055/s-0043-103952
The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations
2006 · Ultrasound in Medicine & Biology · 733 citations
https://doi.org/10.1016/j.ultrasmedbio.2006.05.031
How to perform Contrast-Enhanced Ultrasound (CEUS)
2018 · Ultrasound International Open · 359 citations
https://doi.org/10.1055/s-0043-123931
Liver Transplantation for Hepatocellular Carcinoma: Results of Down-Staging in Patients Initially Outside the Milan Selection Criteria
2008 · American Journal of Transplantation · 358 citations
https://doi.org/10.1111/j.1600-6143.2008.02409.x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat